# US 2026/0097057 A1 · Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease and liver fibrosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097057 A1
- Document ID: US20260097057A1
- Status: Published application
- Kind: A1
- Application number: 19/352,788
- Filed: 2025-10-08
- Published: 2026-04-09
- Earliest claimed: 2024-10-09
- Applicants: AstraZeneca AB
- Inventors: Philip Ambery
- Web page: https://patentgrep.com/patent/US20260097057A1

## CPC

- A61K 31/7034: attached to a carbocyclic compound, e.g. phloridzin
- A61K 31/497: containing further heterocyclic rings
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 13/12: of the kidneys
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods for treating chronic kidney disease and liver fibrosis in patients using a fixed-dose combination of zibotentan and dapagliflozin are disclosed.

## Claims

### Claim 1

A method of treating liver fibrosis in a human patient who has chronic kidney disease (CKD), the method comprising administering to the patient a fixed-dose combination of zibotentan and dapagliflozin in an amount effective to treat the patient's liver fibrosis.

### Claim 2 (depends on 1)

The method of claim 1, wherein the patient has CKD and fibrosis.

### Claim at position 3

3-22. (canceled)

### Claim 23 (depends on 1)

The method according to claim 1, wherein the patient is naïve to a sodium-glucose cotransporter-2 (SGLT2) inhibitor.

### Claim 24 (depends on 1)

The method according to claim 1, wherein the patient has an estimated glomerular filtration rate (eGFR) of 20-90 mL/min/1.73 m2.

### Claim 25 (depends on 1)

The method according to claim 1, comprising administering the fixed-dose combination of zibotentan and dapagliflozin to the patient once per day.

### Claim 26 (depends on 1)

The method according to claim 1, comprising administering zibotentan at a dose of 0.25 mg to 5 mg.

### Claim at position 8

27-33. (canceled)

### Claim 34 (depends on 1)

The method according to claim 1, comprising administering dapagliflozin at a dose of 2.5 mg to 10 mg.

### Claim at position 10

35-40. (canceled)

### Claim 41 (depends on 1)

The method according to claim 1, comprising administering zibotentan at a dose of 0.25 mg and dapagliflozin at a dose of 10 mg when the patient has an eGFR that is <45 mL/min/1.73 m2, and administering zibotentan at a dose of 1.5 mg and dapagliflozin at a dose of 10 mg when the patient has an eGFR that is ≥45 mL/min/1.73 m2.

### Claim 42 (depends on 41)

The method according to claim 41, wherein:
(i) the fixed dose combination of zibotentan and dapagliflozin is adjusted from 1.5 mg of zibotentan and 10 mg of dapagliflozin to 0.25 mg of zibotentan and 10 mg of dapagliflozin when the patient's eGFR changes to <45 mL/min/1.73 m2; or
(ii) the fixed dose combination of zibotentan and dapagliflozin is adjusted from 0.25 mg of zibotentan and 10 mg of dapagliflozin to 1.5 mg of zibotentan and 10 mg of dapagliflozin when the patient's eGFR changes to >45 mL/min/1.73 m2.

### Claim 43

(canceled)

### Claim 44 (depends on 1)

The method according to claim 1, wherein administration of the fixed-dose combination of zibotentan and dapagliflozin reduces the patient's nonalcoholic fatty liver disease (NAFLD) fibrosis score (NFS) to below 0.675.

### Claim 45 (depends on 1)

The method according to claim 1, wherein the patient achieves partial remission or remission.

### Claim 46 (depends on 1)

The method according to claim 1, wherein administration of the fixed-dose combination of zibotentan and dapagliflozin does not increase the patient's NFS relative to a dosing regimen in which the patient receives dapagliflozin alone.

### Claim 47 (depends on 1)

The method according to claim 1, wherein administration of the fixed-dose combination of zibotentan and dapagliflozin reduces the risk of increased NFS in the patient relative to a dosing regimen in which the patient receives dapagliflozin alone.

### Claim 48 (depends on 1)

The method according to claim 1, wherein administration of the fixed-dose combination of zibotentan and dapagliflozin reduces the patient's liver fibrosis relative to a dosing regimen in which the patient receives dapagliflozin alone.

### Claim 49 (depends on 1)

The method according to claim 1, wherein administration of the fixed-dose combination of zibotentan and dapagliflozin reduces the patient's liver fibrosis and reduces the patient's UACR relative to a dosing regimen in which the patient receives dapagliflozin alone.

### Claim 50 (depends on 1)

The method according to claim 1, wherein administration of the fixed-dose combination of zibotentan and dapagliflozin increases (i) the patient's platelet count, serum albumin, or both platelet count and serum albumin; and/or (ii) the patient's aspartate aminotransferase (AST) level, alanine aminotransferase (ALT) level, or both AST and ALT levels.

### Claim 51

(canceled)

### Claim 52 (depends on 1)

The method according to claim 1, wherein the method reduces levels of one or more of MCP-1, IL-6, and high-sensitivity C-reactive protein (hsCRP).

### Claim 53

(canceled)

### Claim 54 (depends on 1)

The method according to claim 1, wherein the method results in a reduction in insulin resistance as shown by assessment of Homeostatic Model Assessment version 2-Insulin Resistance (HOMA2-IR).

### Claim 55 (depends on 1)

The method according to claim 1, wherein the method reduces levels of one or more of proprotein convertase subtilisin/kexin type 9 (PCSK9), lipoprotein (a) (Lp(a)), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (ApoB).

### Claim 56 (depends on 55)

The method according to claim 55, wherein the low-density lipoprotein cholesterol (LDL-C)/Apolipoprotein B (ApoB) ratio is increased.
